REZILIENT2: Phase 2 study of zipalertinib in patients with advanced NSCLC with exon 20 insertions and other uncommon EGFR mutations Meeting Abstract
| Authors: | Yu, H. A.; Besse, B.; Nishio, M.; Cheng, Y.; Wei, L.; Wacheck, V.; Heymach, J. V. |
| Abstract Title: | REZILIENT2: Phase 2 study of zipalertinib in patients with advanced NSCLC with exon 20 insertions and other uncommon EGFR mutations |
| Meeting Title: | 2023 North America Conference on Lung Cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 19 |
| Issue: | 7 Suppl. |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-07-01 |
| Start Page: | e36 |
| End Page: | e37 |
| Language: | English |
| ACCESSION: | WOS:001277064200078 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2024.05.312 |
| Notes: | Meeting Abstract: PP01.81 -- Source: Wos |
